To include your compound in the COVID-19 Resource Center, submit it here.

Long-term data help two drugs sway ICER in drug price report

How long-term data helped justify Revlimid, Genovya price increases to ICER where other drugs faltered

An analysis by the Institute for Clinical and Economic Review of price increases for some of the costliest drugs in the U.S. has found that seven of nine were not supported by new clinical evidence, resulting in what ICER called an unjustified increase in total drug spending of $5.1 billion over two years.

While ICER deemed long-term data from multiple myeloma drug Revlimid and HIV therapy Genovya supported price increases for those drugs, seven of the other costliest drugs failed to meet that standard.

Most of the companies with products surveyed in the report, published Tuesday, criticized ICER for what they considered a narrow view of supportive clinical evidence.

Humira adalimumab from AbbVie Inc. (NASDAQ:ABBV) and Rituxan rituximab from Roche (SIX:ROG; OTCQX:RHHBY), which topped the list with net price increases of 16% and 24%, respectively, did not make the grade. Humira’s net price increase translated into a $1.9 billion increase in spending over the two

Read the full 1548 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers